Access to new licensed medicines

Patient and Public Involvement Group of the Scottish Medicines Consortium (SMC)

The Patient and Public Involvement Group (PAPIG) of the Scottish Medicines Consortium (SMC) is aware of the further consultation and hearing of evidence on the 18th September 2012 regarding SMC, Area Drug and Therapeutics Committees (ADTCs) and the Individual Patient Treatment Request (IPTR) process. PAPIG’s role is to represent the Patient and Public interest within the Scottish Medicines Consortium. However PAPIG acknowledges that some patients have concerns regarding access, perceived limitations, and confusion around the IPTR process. PAPIG therefore supports the further hearing of evidence in order to clarify the process.

Patient and Public Involvement Group of the Scottish Medicines Consortium
30 August 2012